1. Home
  2. GPAT vs SAGE Comparison

GPAT vs SAGE Comparison

Compare GPAT & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPAT
  • SAGE
  • Stock Information
  • Founded
  • GPAT 2020
  • SAGE 2010
  • Country
  • GPAT United States
  • SAGE United States
  • Employees
  • GPAT N/A
  • SAGE N/A
  • Industry
  • GPAT
  • SAGE Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPAT
  • SAGE Health Care
  • Exchange
  • GPAT NYSE
  • SAGE Nasdaq
  • Market Cap
  • GPAT 365.5M
  • SAGE 413.9M
  • IPO Year
  • GPAT 2024
  • SAGE 2014
  • Fundamental
  • Price
  • GPAT $10.57
  • SAGE $9.30
  • Analyst Decision
  • GPAT
  • SAGE Hold
  • Analyst Count
  • GPAT 0
  • SAGE 18
  • Target Price
  • GPAT N/A
  • SAGE $10.06
  • AVG Volume (30 Days)
  • GPAT 159.0K
  • SAGE 2.4M
  • Earning Date
  • GPAT 01-01-0001
  • SAGE 07-30-2025
  • Dividend Yield
  • GPAT N/A
  • SAGE N/A
  • EPS Growth
  • GPAT N/A
  • SAGE N/A
  • EPS
  • GPAT 0.36
  • SAGE N/A
  • Revenue
  • GPAT N/A
  • SAGE $47,404,000.00
  • Revenue This Year
  • GPAT N/A
  • SAGE $102.21
  • Revenue Next Year
  • GPAT N/A
  • SAGE $43.01
  • P/E Ratio
  • GPAT $29.58
  • SAGE N/A
  • Revenue Growth
  • GPAT N/A
  • SAGE N/A
  • 52 Week Low
  • GPAT $9.98
  • SAGE $4.62
  • 52 Week High
  • GPAT $10.64
  • SAGE $13.47
  • Technical
  • Relative Strength Index (RSI)
  • GPAT N/A
  • SAGE 78.92
  • Support Level
  • GPAT N/A
  • SAGE $6.44
  • Resistance Level
  • GPAT N/A
  • SAGE $9.33
  • Average True Range (ATR)
  • GPAT 0.00
  • SAGE 0.26
  • MACD
  • GPAT 0.00
  • SAGE 0.33
  • Stochastic Oscillator
  • GPAT 0.00
  • SAGE 98.98

About GPAT GP-ACT III ACQUISITION CORP

GP-Act III Acquisition Corp is a blank check company.

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Share on Social Networks: